Institution
Charles University in Prague
Education•Prague, Czechia•
About: Charles University in Prague is a education organization based out in Prague, Czechia. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 32392 authors who have published 74435 publications receiving 1804208 citations.
Topics: Population, Large Hadron Collider, Czech, Magnetization, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: High-resolution genome-wide copy number analyses revealed cryptic NUP98/NSD1 translocations in 3 of 92 cytogenetically normal (CN)-AML cases, identifying a previously unrecognized group of young AML patients, with distinct characteristics and dismal prognosis, for whom new treatment strategies are urgently needed.
247 citations
••
TL;DR: In this paper, the authors examine how to quantify asymmetries in volatility spillovers that emerge due to bad and good volatility and find that the overall intra-market connectedness of U.S. stocks increased substantially during the recent financial crisis.
247 citations
••
TL;DR: TRF-budesonide 16 mg/day, added to optimised RAS blockade, reduced proteinuria in patients with IgA nephropathy, indicative of a reduced risk of future progression to end-stage renal disease.
247 citations
••
University of Barcelona1, University of California, San Francisco2, University of Pennsylvania3, Johns Hopkins University4, Charles University in Prague5, Charité6, Vita-Salute San Raffaele University7, Hospital Clínico San Carlos8, university of lille9, University of Düsseldorf10, University of Calgary11, University of Zurich12, University of Sydney13, University of Copenhagen14, Cleveland Clinic15, University of Texas Southwestern Medical Center16, Moorfields Eye Hospital17, New York University18
TL;DR: The results provide evidence of the usefulness of monitoring peripapillary retinal nerve fibre layer thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis.
Abstract: Summary Background Most patients with multiple sclerosis without previous optic neuritis have thinner retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre layer (pRNFL) thickness and macular volume in eyes with no history of optic neuritis as a biomarker of disability worsening in a cohort of patients with multiple sclerosis who had at least one eye without optic neuritis available. Methods In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association of pRNFL thickness or macular volume at baseline in eyes without optic neuritis with the risk of subsequent disability worsening by use of proportional hazards models that included OCT metrics and age, disease duration, disability, presence of previous unilateral optic neuritis, and use of disease-modifying therapies as covariates. Findings 879 patients with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive multiple sclerosis (n=141) were included in the primary analyses. Disability worsening occurred in 252 (29%) of 879 patients with multiple sclerosis after a median follow-up of 2·0 years (range 0·5–5 years). Patients with a pRNFL of less than or equal to 87 μm or less than or equal to 88 μm (measured with Spectralis or Cirrus OCT devices) had double the risk of disability worsening at any time after the first and up to the third years of follow-up (hazard ratio 2·06, 95% CI 1·36–3·11; p=0·001), and the risk was increased by nearly four times after the third and up to the fifth years of follow-up (3·81, 1·63–8·91; p=0·002). We did not identify meaningful associations for macular volume. Interpretation Our results provide evidence of the usefulness of monitoring pRNFL thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis. Funding Instituto de Salud Carlos III.
247 citations
••
Ludwig Maximilian University of Munich1, University of Würzburg2, University of Kiel3, Goethe University Frankfurt4, Humboldt University of Berlin5, University of Ulm6, University of Bologna7, Charles University in Prague8, University of Cologne9, University of Tübingen10, Saarland University11, Institut Gustave Roussy12, Drug Abuse Resistance Education13, University of Paris14, Paris Diderot University15
TL;DR: Using the Ki-67 index is superior to using cytology and growth pattern as prognostic factors in MCL and shows a refined risk stratification, reflecting their strong complementary prognostic effects while integrating the most relevant prognostic Factors available in clinical routine.
Abstract: PurposeMantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome is associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. By using the cohort from the European MCL Younger and MCL Elderly trials, we aimed to evaluate the additional prognostic impact of cytology and growth pattern and to improve risk stratification with the Ki-67 index and MIPI.Patients and MethodsDiagnostic tumor biopsies were reviewed by the European Mantle Cell Lymphoma Pathology Panel to determine Ki-67 index by using published guidelines, cytology, and growth pattern. We evaluated prognostic effects for overall survival (OS) by Cox regression. For the cohort used for MIPI-b development (German Low-Grade Lymphoma Study Group [GLSG] 1996 an...
247 citations
Authors
Showing all 32719 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Petersen | 178 | 1091 | 153067 |
P. Chang | 170 | 2154 | 151783 |
Vaclav Vrba | 141 | 1298 | 95671 |
Milos Lokajicek | 139 | 1511 | 98888 |
Christopher D. Manning | 138 | 499 | 147595 |
Yves Sirois | 137 | 1334 | 95714 |
Rupert Leitner | 136 | 1201 | 90597 |
Gerald M. Reaven | 133 | 799 | 80351 |
Roberto Sacchi | 132 | 1186 | 89012 |
S. Errede | 132 | 1481 | 98663 |
Mark Neubauer | 131 | 1252 | 89004 |
Peter Kodys | 131 | 1262 | 85267 |
Panos A Razis | 130 | 1287 | 90704 |
Vit Vorobel | 130 | 919 | 79444 |
Jehad Mousa | 130 | 1226 | 86564 |